An EU KOL describes endometrial cancer diagnosis and treatment considerations with an assessment of quality-of-life changes after treatment. Ongoing clinical trials for novel medicines are also covered in addition to unmet needs and overall treatment availability for patients in the indication.

This interview was conducted on 10 November 2025.

If you are a Datamonitor Healthcare client, you may access the interview from our KOL Insight channel.

If you are a KOL Insight subscriber, you may also access the interview from our KOL Insight portal.

Biomedtracker’s KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900. 

For our disclosures, please read the Biomedtracker Research Standards.